Galectin-3-IN-1

• CAT Number: I043894
• CAS Number: 1989627-40-8
• Molecular Formula: C18H26O10S
• Molecular Weight: 434.46
• Purity: ≥95%
• Synonyms: (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-prop-2-ynoxyoxan-2-yl]sulfanyl-6-(hydroxymethyl)-4-prop-2-ynoxyoxane-3,5-diol
• InChI: InChI=1S/C18H26O10S/c1-3-5-25-15-11(21)9(7-19)27-17(13(15)23)29-18-14(24)16(26-6-4-2)12(22)10(8-20)28-18/h1-2,9-24H,5-8H2/t9-,10-,11+,12+,13-,14-,15+,16+,17+,18+/m1/s1
• InChIKey: XBXOXPJSVPXLNY-USCYINILSA-N
• SMILES: C#CCO[C@H]1[C@H]([C@H](O[C@H]([C@@H]1O)S[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)OCC#C)O)CO)O

Galectin-3-IN-1（Cat No.:I043894）is a small molecule inhibitor that targets galectin-3, a protein involved in various cellular processes such as cell adhesion, migration, and inflammation. Galectin-3 is overexpressed in several diseases, including cancer, fibrosis, and cardiovascular conditions, contributing to disease progression. By inhibiting galectin-3, Galectin-3-IN-1 has the potential to reduce inflammation, modulate immune responses, and limit tumor growth and metastasis. It is being studied for its therapeutic applications in treating cancer, fibrotic diseases, and other conditions where galectin-3 plays a critical role. Ongoing research aims to evaluate its clinical efficacy and safety.